Drug Approval | August 18, 2021
Novartis secures new approval in China for Cosentyx in pediatric psoriasis
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
